The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI ...

Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was ...

Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with microsatellite instable tumors.

Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member ...

BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announced today that its comprehensive genomic profiling assay Northstar ...

Prevent Cancer Foundation's 2025 Early Detection Survey showed that only about half of U.S. adults 21 years and older said ...

Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

The team is optimizing the cancer genome analysis system to integrate it into CRC diagnosis and tailor treatments based on genetic mutations.

Results from a meta-analysis suggest patients with resectable dMMR/MSI-H gastric cancer can forgo perioperative chemotherapy.

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the treatment of adult and pediatric patients aged 12 years and older with ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

The Food and Drug Administration announced it has approved nivolumab, or Opdivo, marketed by Bristol Myers (BMY) Squibb, with ipilimumab, or ...